Search

Your search keyword '"Thibaud, Santiago"' showing total 165 results

Search Constraints

Start Over You searched for: Author "Thibaud, Santiago" Remove constraint Author: "Thibaud, Santiago"
165 results on '"Thibaud, Santiago"'

Search Results

1. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.

2. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.

3. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.

4. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

6. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis

7. Interventions and outcomes of patients with multiple myeloma receiving salvage treatment after BCMA-directed CAR T therapy

8. Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

9. Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

10. Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

11. Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

13. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

14. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

15. P-043 Leveraging wearable devices for remote patient monitoring facilitate earlier CRS detection following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): early results from an IIT

18. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

19. Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

20. Extramedullary Relapse Post CAR-T

21. Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

22. Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

23. Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

24. Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

25. Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support

26. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients

27. P-078: Targeted sequencing in a diverse real-world cohort of multiple myeloma patients reveals pathogenic mutations of likely germline origin in BRCA2 and other DNA damage repair genes

29. Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

30. Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

31. Pathogenic Germline Variants in Multiple Myeloma

32. P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma

33. Abstract 868: Heritable cancer mutations in multiple myeloma

35. Timing of Vaccination Impacts Serological Response to COVID-19 Myeloma Patients after BCMA-Targeted CAR T

38. SOHO State of the Art Updates and Next Questions: Pathology and Pathogenesis of Nodal Peripheral T-Cell Lymphomas.

39. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19

44. Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study

47. HIV portends a poor prognosis in myelodysplastic syndromes

Catalog

Books, media, physical & digital resources